A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Dermatology Times September 2024 Print Recap
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Promising Long-term Results for ESK-001 in Psoriasis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Vitiligo News: The Year Thus Far
Dermatology Conferences and Meetings Calendar 2024: October